Having established that EphA3 and EphA2 together are promising molecular targets in GBM tumor cells, tumor neovasculature (EphA2) [15], tumor-initiating [12, 17] and tumor-infiltrating cells of monocytic origin, we focused on combinatorial targeting of these receptors. Here, EPHA2 is linked to neoplasm.